U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Reduced alpha/beta synthesis ratio

MedGen UID:
868731
Concept ID:
C4023136
Finding
HPO: HP:0011907

Definition

A reduction in the ratio of production of alpha globin to that of beta globin. This is the major abnormality in the various forms of alpha thalassemia. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVReduced alpha/beta synthesis ratio

Conditions with this feature

alpha Thalassemia
MedGen UID:
1434
Concept ID:
C0002312
Disease or Syndrome
Alpha-thalassemia (a-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four a-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three a-globin genes; --/-a). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.
Acquired hemoglobin H disease
MedGen UID:
108433
Concept ID:
C0585216
Neoplastic Process
An acquired form of alpha-thalassemia characterized by a myelodysplastic syndrome (MDS) or more rarely a myeloproliferative disease (MPD) associated with hemoglobin H disease (HbH).
Alpha thalassemia-X-linked intellectual disability syndrome
MedGen UID:
337145
Concept ID:
C1845055
Disease or Syndrome
Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID). Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip with coarsening of the facial features over time. While all affected individuals have a normal 46,XY karyotype, genital anomalies comprise a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia, to normal-appearing female external genitalia. Alpha-thalassemia, observed in about 75% of affected individuals, is mild and typically does not require treatment. Osteosarcoma has been reported in a few males with germline pathogenic variants.
Hemoglobin H disease
MedGen UID:
468531
Concept ID:
C3161174
Disease or Syndrome
Hemoglobin H disease is a subtype of alpha-thalassemia (see 604131) in which patients have compound heterozygosity for alpha(+)-thalassemia, caused by deletion of one alpha-globin gene, and for alpha(0)-thalassemia, caused by deletion in cis of 2 alpha-globin genes (summary by Lal et al., 2011). When 3 alpha-globin genes become inactive because of deletions with or without concomitant nondeletional mutations, the affected individual has only 1 functional alpha-globin gene. These people usually have moderate anemia and marked microcytosis and hypochromia. In affected adults, there is an excess of beta-globin chains within erythrocytes that will form beta-4 tetramers, also known as hemoglobin H (summary by Chui et al., 2003). Hb H disease is usually caused by the combination of alpha(0)-thalassemia with deletional alpha(+)-thalassemia, a combination referred to as 'deletional' Hb H disease. In a smaller proportion of patients, Hb H disease is caused by an alpha(0)-thalassemia plus an alpha(+)-thalassemia point mutation or small insertion/deletion. Such a situation is labeled 'nondeletional' Hb H disease. Patients with nondeletional Hb H disease are usually more anemic, more symptomatic, more prone to have significant hepatosplenomegaly, and more likely to require transfusions (summary by Lal et al., 2011).

Professional guidelines

PubMed

Kitamura K, Tomita K
Clin Exp Nephrol 2012 Feb;16(1):44-8. Epub 2011 Nov 1 doi: 10.1007/s10157-011-0506-1. PMID: 22038264
Trent RJ, Le H, Yu B
Prenat Diagn 1998 Jun;18(6):591-8. PMID: 9664605

Recent clinical studies

Etiology

Kath J, Du W, Martini S, Elsallab M, Franke C, Hartmann L, Drosdek V, Glaser V, Stein M, Schmueck-Henneresse M, Reinke P, Volk HD, Abou-El-Enein M, Wagner DL
Blood Adv 2023 Aug 8;7(15):4124-4134. doi: 10.1182/bloodadvances.2022009397. PMID: 37196643Free PMC Article
Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB
Proc Natl Acad Sci U S A 2021 Aug 17;118(33) doi: 10.1073/pnas.2102191118. PMID: 34385305Free PMC Article
Zhang C, Wei L, Zeng F, Zhang T, Sun Y, Shen Y, Wang G, Ma J, Zhang J
Biomed Res Int 2021;2021:5561974. Epub 2021 Jul 24 doi: 10.1155/2021/5561974. PMID: 34350292Free PMC Article
Wakayama Y, Inoue M, Kojima H, Yamashita S, Shibuya S, Jimi T, Hara H, Matsuzaki Y, Oniki H, Kanagawa M, Kobayashi K, Toda T
Histol Histopathol 2008 Dec;23(12):1425-38. doi: 10.14670/HH-23.1425. PMID: 18830929
Taranta A, Fortunati D, Longo M, Rucci N, Iacomino E, Aliberti F, Facciuto E, Migliaccio S, Bardella MT, Dubini A, Borghi MO, Saraifoger S, Teti A, Bianchi ML
J Bone Miner Res 2004 Jul;19(7):1112-21. Epub 2004 Mar 22 doi: 10.1359/JBMR.040319. PMID: 15176994

Diagnosis

Zhang C, Wei L, Zeng F, Zhang T, Sun Y, Shen Y, Wang G, Ma J, Zhang J
Biomed Res Int 2021;2021:5561974. Epub 2021 Jul 24 doi: 10.1155/2021/5561974. PMID: 34350292Free PMC Article
Oeckl P, Metzger F, Nagl M, von Arnim CA, Halbgebauer S, Steinacker P, Ludolph AC, Otto M
Mol Cell Proteomics 2016 Oct;15(10):3126-3138. Epub 2016 Aug 9 doi: 10.1074/mcp.M116.059915. PMID: 27507836Free PMC Article
Carlson DJ, Stewart RD, Semenenko VA
Med Phys 2006 Sep;33(9):3105-15. doi: 10.1118/1.2229427. PMID: 17022202
Weaver JU, Thaventhiran L, Noonan K, Burrin JM, Taylor NF, Norman MR, Monson JP
Clin Endocrinol (Oxf) 1994 Nov;41(5):639-48. doi: 10.1111/j.1365-2265.1994.tb01830.x. PMID: 7828353
Honig GR, Shamsuddin M, Mason RG, Vida LN, Tremaine LM, Tarr GE, Shahidi NT
Blood 1980 Jan;55(1):131-7. PMID: 7350933

Therapy

Song K, Nho CW, Ha IJ, Kim YS
J Nat Prod 2020 Sep 25;83(9):2559-2566. Epub 2020 Sep 3 doi: 10.1021/acs.jnatprod.0c00043. PMID: 32881525
Chen X, Hill M, Vander Lugt M, Escolar M, Fang Z, Chen W, Szabolcs P
Cytotherapy 2020 Mar;22(3):149-157. Epub 2020 Feb 21 doi: 10.1016/j.jcyt.2020.01.005. PMID: 32089448Free PMC Article
Frustaci A, Chimenti C, Pieroni M, Salvatori L, Morgante E, Sale P, Ferretti E, Petrangeli E, Gulino A, Russo MA
Mod Pathol 2006 Jun;19(6):755-65. doi: 10.1038/modpathol.3800594. PMID: 16575400
Baldacci A, Thormann W
Electrophoresis 2005 May;26(10):1969-77. doi: 10.1002/elps.200410301. PMID: 15832300
Koukourakis MI
Semin Oncol 2002 Dec;29(6 Suppl 19):42-6. doi: 10.1053/sonc.2002.37359. PMID: 12577243

Prognosis

Murphy WA, Beaudoin JJ, Laitinen T, Sjöstedt N, Malinen MM, Ho H, Swaan PW, Honkakoski P, Brouwer KLR
Mol Pharmacol 2021 Dec;100(6):599-608. Epub 2021 Oct 1 doi: 10.1124/molpharm.121.000345. PMID: 34599072Free PMC Article
Carlson DJ, Stewart RD, Semenenko VA
Med Phys 2006 Sep;33(9):3105-15. doi: 10.1118/1.2229427. PMID: 17022202
Koukourakis MI
Semin Oncol 2002 Dec;29(6 Suppl 19):42-6. doi: 10.1053/sonc.2002.37359. PMID: 12577243
van der Vliet HJ, von Blomberg BM, Hazenberg MD, Nishi N, Otto SA, van Benthem BH, Prins M, Claessen FA, van den Eertwegh AJ, Giaccone G, Miedema F, Scheper RJ, Pinedo HM
J Immunol 2002 Feb 1;168(3):1490-5. doi: 10.4049/jimmunol.168.3.1490. PMID: 11801694
Böhm J, Niskanen L, Kiraly K, Kellokoski J, Eskelinen M, Hollmen S, Alhava E, Kosma VM
J Clin Endocrinol Metab 2000 Dec;85(12):4806-11. doi: 10.1210/jcem.85.12.7079. PMID: 11134147

Clinical prediction guides

Murphy WA, Beaudoin JJ, Laitinen T, Sjöstedt N, Malinen MM, Ho H, Swaan PW, Honkakoski P, Brouwer KLR
Mol Pharmacol 2021 Dec;100(6):599-608. Epub 2021 Oct 1 doi: 10.1124/molpharm.121.000345. PMID: 34599072Free PMC Article
Oeckl P, Metzger F, Nagl M, von Arnim CA, Halbgebauer S, Steinacker P, Ludolph AC, Otto M
Mol Cell Proteomics 2016 Oct;15(10):3126-3138. Epub 2016 Aug 9 doi: 10.1074/mcp.M116.059915. PMID: 27507836Free PMC Article
Steckelbroeck S, Oyesanmi B, Jin Y, Lee SH, Kloosterboer HJ, Penning TM
J Pharmacol Exp Ther 2006 Mar;316(3):1300-9. Epub 2005 Dec 8 doi: 10.1124/jpet.105.091587. PMID: 16339391
Baldacci A, Thormann W
Electrophoresis 2005 May;26(10):1969-77. doi: 10.1002/elps.200410301. PMID: 15832300
Campana D, Farrant J, Inamdar N, Webster AD, Janossy G
J Immunol 1990 Sep 15;145(6):1675-80. PMID: 2391416

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...